A phase II randomized study of lapatinib in combination with capecitabine, vinorelbine or gemcitabine as first or second line-therapy in patients with HER2 positive metastatic breast cancer progressing after taxane (LACOG 0801)

Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Search DSpace


My Account